GLP-1 Combination Therapy Trial Results: A Roundup
Several companies are studying GLP-1 drugs combined with other mechanisms — amylin analogs, myostatin inhibitors — to improve efficacy or offset muscle loss.
By the GLP Semaglutide editorial team · Last updated November 28, 2025
Beyond single-molecule GLP-1 drugs, several companies are studying combination approaches — pairing a GLP-1 agonist with an amylin analog, a myostatin/activin inhibitor aimed at preserving muscle mass, or other complementary mechanisms.
The rationale
Combination approaches aim either to improve overall efficacy beyond what a single mechanism achieves, or to offset specific side effects (like lean mass loss) associated with rapid weight loss, according to trial designs published by sponsor companies.
Early stage, evolving fast
Most combination approaches remain in early-to-mid-stage trials. Results at this stage are directional, not confirmatory, and specific efficacy figures should be sourced from the trial registry or peer-reviewed publication rather than secondary summaries.
Primary sources